The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books

Here’s a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peaks

(Biotech stocks hitting 52-week highs on Sept. 3)

Ardelyx Inc (NASDAQ: ARDX) (reported positive results from a late-stage of its lead compound tenapanor in combination with phosphate binders to treat hyperphosphatemia in patients with chronic kidney disease on dialysis) China Biologic Products Holdings Inc (NASDAQ: CBPO) DURECT Corporation (NASDAQ: DRRX) Insulet Corporation (NASDAQ: PODD) (announced private offering of convertible senior notes) Lipocine Inc (NASDAQ: LPCN) NextCure Inc (NASDAQ: NXTC) The Medicines Company (NASDAQ: MDCO) (announced positive Phase 3 results for inclisiran) Down In The Dumps

(Biotech stocks hitting 52-week lows on Sept. 3)

Adamis Pharmaceuticals Corp (NASDAQ: ADMP) Aduro BioTech Inc (NASDAQ: ADRO) Aerie Pharmaceuticals Inc (NASDAQ: AERI) Agios Pharmaceuticals Inc (NASDAQ: AGIO) Alimera Sciences Inc (NASDAQ: ALIM) Assembly Biosciences Inc (NASDAQ: ASMB) BIOLINERX LTD/S ADR (NASDAQ: BLRX) (announced completion of dose-escalation part of the Phase 1/2a study of AGI-134) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) DelMar Pharmaceuticals Inc (NASDAQ: DMPI) Esperion Therapeutics Inc (NASDAQ: ESPR) Gemphire Therapeutics Inc (NASDAQ: GEMP) HTG Molecular Diagnostics Inc (NASDAQ: HTGM) ICU Medical, Incorporated (NASDAQ: ICUI) Kezar Life Sciences Inc (NASDAQ: KZR) Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) Ligand Pharmaceuticals Inc. (NASDAQ: LGND) Mirum Pharmaceuticals Inc (NASDAQ: MIRM) Nephros, Inc. (NASDAQ: NEPH) ProQR Therapeutics NV (NASDAQ: PRQR) Protalix Biotherapeutics Inc (NYSE: PLX) Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Rubius Therapeutics Inc (NASDAQ: RUBY) Sarepta Therapeutics Inc (NASDAQ: SRPT) Synlogic Inc (NASDAQ: SYBX) Wright Medical Group NV (NASDAQ: WMG)

See Also: The Week Ahead In Biotech: Cardiology, Analyst Conferences In The Spotlight

Stocks In Focus Puma’s Breast Cancer Drug Gets Orphan Drug Designation For Expanded Indication

Puma Biotechnology Inc (NASDAQ: PBYI) announced the FDA granted Orphan Drug Designation to its Nerlynx for the treatment of

Read More Here...

Bookmark the permalink.

Comments are closed.